Comparison of Clinical outcomes between angio-guided spot stenting and angio-guided entire stenting using Zotarolimus eluting stent with the patients with diffuse long coronary lesions.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003082

Enrollment

470

Registered

2018-08-13

Start date

2016-09-30

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : In angio-guided angio-guided stent implantation with diffuse long lesion, stent placement with the stenosis centered on the most severe stenosis was performed and spot stenting was pe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age Only patients with stable angina or unstable angina over 19 years 2. Reference diameter = 2.5 mm lesion length = 25 mm 3. De novo lesions with% Diameter stenosis =50% 4. Patient with Core lesion for spot stenting For definitions of core lesions, see Clinical Trial Methods.

Exclusion criteria

Exclusion criteria: 1. Ascitic (aspirin), clopidogrel (Clopidogrel) and anti-platelet agents, such as those who are contraindicated 2. Left-sided lesions (left main lesion, internal diameter stenosis (diameter stenosis) =50%) 3. A recent hematologic disease or white blood cell count of 3000 / mm3 and / or platelet count of 100,000 / mm3. Who show less 4. Severe epicardial disease with a longevity of less than 1 year 5. Those who plan to perform two stenting operations on branch vessels and branch lesions with basilar lesions 6. Patients who underwent emergency stenting after a diagnosis of myocardial infarction within 24 hours (STEMI, NSTEMI can be enrolled after 24 hours) 7. Who can not comply with the research plan

Design outcomes

Primary

Measure	Time frame
cardiac death;Target vessel myocardial infarction;STEMI and NSTEMI- Including periprocedural myocardial infarction;Ischemic driven target vessel revascularization	—

Secondary

Measure	Time frame
All death;STEMI and NSTEMI-periprocedural MI;Target lesion revascularization (TLR);target vessel revascularization (Non-TVR),;Stent thrombosis	—

Countries

Korea, Republic of

Contacts

Public ContactSeung Rha

Koera University Guro Hospital

swrha617@yahoo.co.kr+82-2-2626-3020

Outcome results